NCT00742599已完成3 期
Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (Randomized, Double-blind, Parallel-assignment , Placebo-controlled Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 80
- 主要终点
- Presence or absence of gastric peristalsis (central evaluation by independent evaluator) No gastric peristalsis is defined as when patients have no gastric peristalsis at both 2 minutes post-dose and the end of endoscopy.
研究概览
简要总结
Patients who require gastric endoscopy will receive an intragastric single dose of NPO-11 20 mL. The superiority of NPO-11 to placebo as a premedication for endoscopy will be verified in a randomized, double-blind, parallel-assignment design based on the percentage of patients having no gastric peristalsis at both 2 minutes post-dose and the end of endoscopy (primary outcome measure).
The safety of NPO-11 will be evaluated based on adverse events and adverse drug reactions (ADRs) observed between administration and seven days after administration in comparison with the placebo group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inpatients or outpatients of either sex who visit medical institutions for treatment or follow-up of confirmed or suspected upper gastrointestinal disease (symptoms) and meet the criteria (1) and (2) below will be enrolled in the study. Patients have to provide written informed consent for voluntary participation in the study.
- •Patients who need gastric endoscopy (except for endoscopy with a scope of <9 mm in diameter, emergency endoscopy and endoscopy for comprehensive medical examination)
- •Patients who are older than 20 years at the time of consent
排除标准
- •Patients who meet any of the following criteria will be excluded from the study. The criteria (2) to (5) will be confirmed during endoscopy. Patients who meet any of these criteria will be withdrawn from the study at the time of confirmation.
- •Patients with a history of surgery to the upper gastrointestinal tract
- •Patients with severe gastric stenosis or deformation which makes observation of gastric peristalsis difficult
- •Patients with upper gastrointestinal bleeding which requires hemostasis
- •Patients with reflux esophagitis (Los Angeles classification: B, C or D)
- •Patients with gastric or duodenal ulcers in active stage
- •Patients on cancer treatment (chemotherapy or radiotherapy)
- •Patients with impaired cardiac function (NYHA functional classification: III or IV)
- •Patients with a history of shock or hypersensitivity to l-menthol or peppermint oil (mint oil)
- •Patients with a history of shock or hypersensitivity to lidocaine hydrochloride
- •Pregnant or lactating women, women of childbearing potential, or women who plan to become pregnant during the study
- •Patients who have been exposed to NPO-11
- •Patients who have received other investigational drugs within four months before consent or who are participating in other clinical studies
- •Patients otherwise ineligible for participation in the study in the investigator's or subinvestigator's opinion
研究组 & 干预措施
N
Active Comparator
干预措施: NPO-11 (Drug)
P
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Presence or absence of gastric peristalsis (central evaluation by independent evaluator) No gastric peristalsis is defined as when patients have no gastric peristalsis at both 2 minutes post-dose and the end of endoscopy.
时间窗: each evaluation point
次要结局
- Change in gastric peristalsis(each evaluation point)
- Difficulty level of intragastric observation (evaluation by investigator who performs endoscopy)(each evaluation point)
- Adverse events and ADRs observed between administration and 7±3 days after administration(each evaluation point)
研究者
相似试验
已完成
3 期
Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal EndoscopyColon Nos Polypectomy Tubular AdenomaGastric AdenomaGastric CancerNCT01411189Nihon Pharmaceutical Co., Ltd33
已完成
3 期
Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal EndoscopyGastric CancerNCT01411176Nihon Pharmaceutical Co., Ltd85
已完成
3 期
Study of NPO-11 in Patients Undergoing Gastrointestinal EndoscopyPatients Undergoing Gastrointestinal EndoscopyNCT03263910Nihon Pharmaceutical Co., Ltd220
已完成
3 期
Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric EndoscopyStomach DiseasesNCT00745459Nihon Pharmaceutical Co., Ltd100
已完成
2 期
Phase Ⅱ Dose Response Study of NPO-13 in Patients Undergoing Total ColonoscopyBowel DiseaseNCT02265939Nihon Pharmaceutical Co., Ltd132